Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

64Cu-DOTA-B-Fab as A PET Tracer for Evaluating CA6 Expression in Tumors: A First in Human Study

NCT02708511 is registered in ClinicalTrials.gov with Sanjiv Sam Gambhir as lead sponsor.

NCT NCT02708511
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02708511 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
64Cu-DOTA-B-Fab as A PET Tracer for Evaluating CA6 Expression in Tumors: A First in Human Study
Lead sponsor
Sanjiv Sam Gambhir
Phase
Phase 1
Overall status
Terminated
Start date
August 31, 2016
Completion date
October 11, 2017
Enrollment
2 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast carcinoma, ovarian carcinoma